Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 464 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Expansion Clear all

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Interventions: GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Duarte, California • La Jolla, California • Orange, California + 6 more

Conditions: Cutaneous T Cell Lymphoma
Interventions: Ropeginterferon alfa-2b; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
Interventions: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Scottsdale, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 13 more

Conditions: Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions: Nab-Rapamycin, Nivolumab; Drug · Biological
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 12 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions: OrcaGraft (Orca-Q); Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 12 Years to 78 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Duarte, California • Sacramento, California • Stanford, California + 9 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Venetoclax, Bortezomib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: SPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Interventions: Acalabrutinib; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 8
States / cities: Boston, Massachusetts • New Hyde Park, New York • New York, New York + 5 more

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP), Vascular Anomalies
Interventions: RLY-2608, Placebo; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 28
States / cities: Chandler, Arizona • Duarte, California • Fullerton, California + 25 more

Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Interventions: Casdatifan, Cabozantinib, Zimberelimab, Ipilimumab, Tivozanib, Ivonescimab, Axitinib; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more

Conditions: Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions: Tegavivint; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer
Interventions: ART4215, Talazoparib, Niraparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more

Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 22
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more

Conditions: Clear-Cell Renal Carcinoma
Interventions: rhIL-15, Avelumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasm
Interventions: PF-05212384 (gedatolisib), Docetaxel, Cisplatin, Dacomitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: EGFR-Mutant Lung Cancer
Interventions: erlotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions: Mifepristone and Eribulin in combination; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 11
States / cities: Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions: IMGN151, Carboplatin, Bevacizumab, Olaparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more

Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma, Metastatic Retinoblastoma
Interventions: GPC2 CAR T cells; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 1 Year and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
Interventions: PF-07062119, Anti-PD1, Anti-VEGF; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 6 more

Conditions: Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
Interventions: ABBV-927, ABBV-368, ABBV-181, Carboplatin, Nab-paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: Springdale, Arkansas • Santa Rosa, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors